Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
St. Jude Children's Research Hospital
Fred Hutchinson Cancer Center
M.D. Anderson Cancer Center
City of Hope Medical Center
University of Michigan Rogel Cancer Center
Memorial Sloan Kettering Cancer Center
Dana-Farber Cancer Institute
Stanford University
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Children's Hospital Medical Center, Cincinnati
Case Comprehensive Cancer Center
University of Arizona
M.D. Anderson Cancer Center
Thomas Jefferson University
Thomas Jefferson University
Dana-Farber Cancer Institute
University of Rochester
Mayo Clinic
Memorial Sloan Kettering Cancer Center
Fred Hutchinson Cancer Center
St. Jude Children's Research Hospital
Masonic Cancer Center, University of Minnesota
Massachusetts General Hospital
Masonic Cancer Center, University of Minnesota
Roswell Park Cancer Institute
Masonic Cancer Center, University of Minnesota
City of Hope Medical Center
University of Illinois at Chicago
City of Hope Medical Center
Fred Hutchinson Cancer Center
Case Comprehensive Cancer Center
City of Hope Medical Center
City of Hope Medical Center
M.D. Anderson Cancer Center
Thomas Jefferson University
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
Stanford University
St. Petersburg State Pavlov Medical University
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Loyola University
City of Hope Medical Center
Columbia University
Roswell Park Cancer Institute
St. Petersburg State Pavlov Medical University
Indiana University